We recently compiled a list of the Why These 15 Stocks Are Skyrocketing in 2025. In this article, we are going to take a look at where Vir Biotechnology, Inc. (NASDAQ:VIR) stands against the other ...

Vir Biotechnology announced promising results Wednesday for a pair of cancer treatments, and Vir stock catapulted by double digits.

Vir Biotechnology (NASDAQ:VIR – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a ...

Vir Biotechnology Inc (VIR) stock saw a modest uptick, ending the day at $11.2 which represents a slight increase of $0.67 or 6.36% from the prior close of $10.53. The stock opened at $10.48 and ...

Vir Biotechnology's recent share price rally is driven by their promising cancer program. Having shot to over a $1.5B market cap, see if VIR stock is a Buy now.

Vir Biotechnology's Phase 1 data highlights early promise for T-cell engagers targeting HER2-positive tumors and prostate ...

Vir Biotechnology, Inc. (NASDAQ:VIR – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the six ...

Leerink Partners analyst Roanna Ruiz reiterated a Buy rating on Vir Biotechnology (VIR – Research Report) on January 13 and set a price target ...

These initial results provide clinical support for Vir Biotechnology’s in-licensed PRO-XTEN™ masking technology, which is designed to enable the selective activation of TCEs in the tumor ...

At the conference last week in San Francisco, pharmaphorum editor-in-chief Jonah Comstock spoke with Vir Biotechnology CEO ...

On Wednesday, Vir Biotechnology, Inc. (NASDAQ:VIR) presented initial Phase 1 data from two of its dual-masked T-cell engagers (TCEs): VIR-5818, which targets a variety of HER2-expressing solid ...

In a report released today, Gena Wang from Barclays assigned a Buy rating to Vir Biotechnology (VIR – Research Report), with a price target of ...